Adaptimmune Announces that Gwen Binder will leave in January 2019
13 December 2018 - 12:30AM
Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat
cancer, today announced that Gwen Binder, PhD, Chief Technology
Officer, will be leaving the company at the end of January 2019.
Dr. Binder was the first US employee of
Adaptimmune in 2011, transitioning across from the company’s T-cell
translational development collaboration program with the University
of Pennsylvania. She led much of the early clinical development,
manufacturing, translational and more recently research components
of the company.
“Gwen has contributed a tremendous amount to the early phase
technical advancement and progress of our therapies, and to cell
therapy in general,” said James Noble, Adaptimmune’s CEO. “As
Adaptimmune moves into a more clinically focused stage, Gwen
decided it is time to pursue a different path that will allow her
to remain focused on early development and technical innovation and
we wish her every success.”
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T-cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune is currently conducting
clinical trials with SPEAR T-cells targeting MAGE-A4, MAGE-A10, and
AFP across multiple solid tumor indications. The Company is
located in Philadelphia, USA and Oxfordshire, U.K. For more
information, please visit http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on November 6, 2018, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2024 to May 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From May 2023 to May 2024